Search
Maze Therapeutics Inc
MAZEAdd to Watchlist
25.680USD
+0.840+3.38%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
1.28BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Maze Therapeutics Inc is 8.83, ranking 53 out of 389 in the Biotechnology & Medical Research industry. The average price target is 39.50, with a high of 60.00 and a low of 34.00.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
63.500
Target Price
+147.27%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Maze Therapeutics Inc
MAZE
12
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Maze Therapeutics Inc's expected revenue for the next quarter?
Maze Therapeutics Inc's expected revenue is 2.00M.
What is Maze Therapeutics Inc's price target?
Analysts forecast that Maze Therapeutics Inc's price target is USD 39.50, with the highest forecast at USD 60.00 and the lowest forecast at USD 34.00.
How have Maze Therapeutics IncMAZE's recent earnings per share performed?
The market expectation was USD -0.45, while Maze Therapeutics IncMAZE's earnings per share (EPS) for the previous quarter was USD -0.65. EPS for the next quarter is expected at USD -0.73.
What is the analyst rating for Maze Therapeutics Inc?
Based on the ratings of Maze Therapeutics Inc's stock from 12 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
